User menu

The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer

Bibliographic reference Hendlisz, Alain ; Deleporte, Amelie ; Delaunoit, Thierry ; Maréchal, Raphaël ; Peeters, Marc ; et. al. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. In: PLoS One, Vol. 10, no. 9, p. e0138341[1-14] (2015)
Permanent URL http://hdl.handle.net/2078.1/171925
  1. McDermott Ultan, Downing James R., Stratton Michael R., Genomics and the Continuum of Cancer Care, 10.1056/nejmra0907178
  2. Greaves Mel, Maley Carlo C., Clonal evolution in cancer, 10.1038/nature10762
  3. Aparicio Samuel, Caldas Carlos, The Implications of Clonal Genome Evolution for Cancer Medicine, 10.1056/nejmra1204892
  4. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  5. Grothey Axel, Hedrick Eric E., Mass Robert D., Sarkar Somnath, Suzuki Sam, Ramanathan Ramesh K., Hurwitz Herbert I., Goldberg Richard M., Sargent Daniel J., Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107, 10.1200/jco.2007.13.8099
  6. Grothey Axel, Cutsem Eric Van, Sobrero Alberto, Siena Salvatore, Falcone Alfredo, Ychou Marc, Humblet Yves, Bouché Olivier, Mineur Laurent, Barone Carlo, Adenis Antoine, Tabernero Josep, Yoshino Takayuki, Lenz Heinz-Josef, Goldberg Richard M, Sargent Daniel J, Cihon Frank, Cupit Lisa, Wagner Andrea, Laurent Dirk, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, 10.1016/s0140-6736(12)61900-x
  7. Llovet Josep M., Ricci Sergio, Mazzaferro Vincenzo, Hilgard Philip, Gane Edward, Blanc Jean-Frédéric, de Oliveira Andre Cosme, Santoro Armando, Raoul Jean-Luc, Forner Alejandro, Schwartz Myron, Porta Camillo, Zeuzem Stefan, Bolondi Luigi, Greten Tim F., Galle Peter R., Seitz Jean-François, Borbath Ivan, Häussinger Dieter, Giannaris Tom, Shan Minghua, Moscovici Marius, Voliotis Dimitris, Bruix Jordi, Sorafenib in Advanced Hepatocellular Carcinoma, 10.1056/nejmoa0708857
  8. Awada Ahmad, Gil Thierry, Whenham Nicolas, Van Hamme Julie, Besse-Hammer Tatiana, Brendel Erich, Delesen Heinz, Joosten Miranda C., Lathia Chetan D., Loembé Bienvenu A., Piccart-Ghebart Martine, Hendlisz Alain, Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial, 10.1177/0091270010386226
  9. Ott Katja, Weber Wolfgang A., Lordick Florian, Becker Karen, Busch Raymonde, Herrmann Ken, Wieder Hinrich, Fink Ulrich, Schwaiger Markus, Siewert Jörg-Rüdiger, Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction, 10.1200/jco.2006.06.7801
  10. Hoekstra Corneline J., Stroobants Sigrid G., Smit Egbert F., Vansteenkiste Johan, van Tinteren Harm, Postmus Pieter E., Golding Richard P., Biesma Bonne, Schramel Frans J.H.M., van Zandwijk Nico, Lammertsma Adriaan A., Hoekstra Otto S., Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer, 10.1200/jco.2005.01.1189
  11. Rousseau Caroline, Devillers Anne, Sagan Christine, Ferrer Ludovic, Bridji Boumédiène, Campion Loïc, Ricaud Myriam, Bourbouloux Emmanuelle, Doutriaux Isabelle, Clouet Martine, Berton-Rigaud Dominique, Bouriel Catherine, Delecroix Valérie, Garin Etienne, Rouquette Sophie, Resche Isabelle, Kerbrat Pierre, Chatal Jean François, Campone Mario, Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography, 10.1200/jco.2006.05.7406
  12. de Geus-Oei L.F., van Laarhoven H. W. M., Visser E. P., Hermsen R., van Hoorn B. A., Kamm Y. J. L., Krabbe P. F. M., Corstens F. H. M., Punt C. J. A., Oyen W. J. G., Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer, 10.1093/annonc/mdm470
  13. Hendlisz A., Golfinopoulos V., Garcia C., Covas A., Emonts P., Ameye L., Paesmans M., Deleporte A., Machiels G., Toussaint E., Vanderlinden B., Awada A., Piccart M., Flamen P., Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy, 10.1093/annonc/mdr554
  14. SF Barrington, J Clin Oncol (2014)
  15. Cheson Bruce D., Pfistner Beate, Juweid Malik E., Gascoyne Randy D., Specht Lena, Horning Sandra J., Coiffier Bertrand, Fisher Richard I., Hagenbeek Anton, Zucca Emanuele, Rosen Steven T., Stroobants Sigrid, Lister T. Andrew, Hoppe Richard T., Dreyling Martin, Tobinai Kensei, Vose Julie M., Connors Joseph M., Federico Massimo, Diehl Volker, Revised Response Criteria for Malignant Lymphoma, 10.1200/jco.2006.09.2403
  16. BD Cheson, J Clin Oncol (2014)
  17. Kobe C., Dietlein M., Franklin J., Markova J., Lohri A., Amthauer H., Klutmann S., Knapp W. H., Zijlstra J. M., Bockisch A., Weckesser M., Lorenz R., Schreckenberger M., Bares R., Eich H. T., Mueller R.-P., Fuchs M., Borchmann P., Schicha H., Diehl V., Engert A., Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma, 10.1182/blood-2008-06-155820
  18. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations, 10.1016/s0959-8049(99)00229-4
  19. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A., From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, 10.2967/jnumed.108.057307
  20. Baselga José, Segalla José Getúlio Martins, Roché Henri, del Giglio Auro, Pinczowski Hélio, Ciruelos Eva M., Filho Sebastião Cabral, Gómez Patricia, Van Eyll Brigitte, Bermejo Begoña, Llombart Antonio, Garicochea Bernardo, Durán Miguel Ángel Climent, Hoff Paulo Marcelo Gehm, Espié Marc, de Moraes Andre Augusto Junior Gemeinder, Ribeiro Ronaldo Albuquerque, Mathias Clarissa, Gil Gil Miguel, Ojeda Belén, Morales Josefa, Kwon Ro Sunhee, Li Shell, Costa Frederico, Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer, 10.1200/jco.2011.36.7771
  21. Kupsch Petra, Henning Bernhard F., Passarge Katrin, Richly Heike, Wiesemann Katrin, Hilger Ralf A., Scheulen Max E., Christensen Olaf, Brendel Erich, Schwartz Brian, Hofstra Elke, Voigtmann Rudolf, Seeber Siegfried, Strumberg Dirk, Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer, 10.3816/ccc.2005.n.030
  22. Novello Silvia, Vavalà Tiziana, Levra Matteo Giaj, Solitro Federica, Pelosi Ettore, Veltri Andrea, Scagliotti Giorgio V., Early Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography, 10.1016/j.cllc.2012.10.004
  23. Ueno Daiki, Yao Masahiro, Tateishi Ukihide, Minamimoto Ryogo, Makiyama Kazuhide, Hayashi Narihiko, Sano Futoshi, Murakami Takayuki, Kishida Takeshi, Miura Takeshi, Kobayashi Kazuki, Noguchi Sumio, Ikeda Ichiro, Ohgo Yoshiharu, Inoue Tomio, Kubota Yoshinobu, Nakaigawa Noboru, Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course, 10.1186/1471-2407-12-162
  24. Hendlisz Alain, Golfinopoulos Vassilis, Deleporte Amelie, Paesmans Marianne, Mansy Hazem El, Garcia Camilo, Peeters Marc, Annemans Lieven, Vandeputte Caroline, Maetens Marion, Borbath Ivan, Dresse Damien, Houbiers Ghislain, Fried Michael, Awada Ahmad, Piccart Martine, Laethem Jean-Luc Van, Flamen Patrick, Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study, 10.1186/1471-2407-13-190
  25. Giobbie-Hurder Anita, Gelber Richard D., Regan Meredith M., Challenges of Guarantee-Time Bias, 10.1200/jco.2013.49.5283
  26. E Marubini, 414 (1995)
  27. Boellaard Ronald, Oyen Wim J. G., Hoekstra Corneline J., Hoekstra Otto S., Visser Eric P., Willemsen Antoon T., Arends Bertjan, Verzijlbergen Fred J., Zijlstra Josee, Paans Anne M., Comans Emile F. I., Pruim Jan, The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials, 10.1007/s00259-008-0874-2
  28. Gebhart G., Gamez C., Holmes E., Robles J., Garcia C., Cortes M., de Azambuja E., Fauria K., Van Dooren V., Aktan G., Coccia-Portugal M. A., Kim S.-B., Vuylsteke P., Cure H., Eidtmann H., Baselga J., Piccart M., Flamen P., Di Cosimo S., 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO, 10.2967/jnumed.112.119271
  29. Miller A. B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment, 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
  30. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  31. Buvat Irène, Necib Hatem, Garcia Camilo, Wagner Antoine, Vanderlinden Bruno, Emonts Patrick, Hendlisz Alain, Flamen Patrick, Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer, 10.1007/s00259-012-2172-2
  32. Bystrom P., Berglund A., Garske U., Jacobsson H., Sundin A., Nygren P., Frodin J.-E., Glimelius B., Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer, 10.1093/annonc/mdn744
  33. de Geus-Oei L.-F., Vriens D., van Laarhoven H. W.M., van der Graaf W. T.A., Oyen W. J.G., Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review, 10.2967/jnumed.108.057224
  34. Lastoria S., Piccirillo M. C., Caraco C., Nasti G., Aloj L., Arrichiello C., de Lutio di Castelguidone E., Tatangelo F., Ottaiano A., Iaffaioli R. V., Izzo F., Romano G., Giordano P., Signoriello S., Gallo C., Perrone F., Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab, 10.2967/jnumed.113.119909
  35. Jonker Derek J., O'Callaghan Chris J., Karapetis Christos S., Zalcberg John R., Tu Dongsheng, Au Heather-Jane, Berry Scott R., Krahn Marianne, Price Timothy, Simes R. John, Tebbutt Niall C., van Hazel Guy, Wierzbicki Rafal, Langer Christiane, Moore Malcolm J., Cetuximab for the Treatment of Colorectal Cancer, 10.1056/nejmoa071834
  36. Bendell Johanna C., Ervin Thomas J., Senzer Neil N., Richards Donald A., Firdaus Irfan, Lockhart A. Craig, Cohn Allen Lee, Saleh Mansoor N., Gardner Lesa R., Sportelli Peter, Eng Cathy, Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)., 10.1200/jco.2012.30.18_suppl.lba3501
  37. Van Cutsem Eric, Peeters Marc, Siena Salvatore, Humblet Yves, Hendlisz Alain, Neyns Bart, Canon Jean-Luc, Van Laethem Jean-Luc, Maurel Joan, Richardson Gary, Wolf Michael, Amado Rafael G., Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, 10.1200/jco.2006.08.1620
  38. Escudier Bernard, Eisen Tim, Stadler Walter M., Szczylik Cezary, Oudard Stéphane, Staehler Michael, Negrier Sylvie, Chevreau Christine, Desai Apurva A., Rolland Frédéric, Demkow Tomasz, Hutson Thomas E., Gore Martin, Anderson Sibyl, Hofilena Gloria, Shan Minghua, Pena Carol, Lathia Chetan, Bukowski Ronald M., Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial, 10.1200/jco.2008.19.5511